Wellington Management Group LLP Sells 90,290 Shares of Janux Therapeutics, Inc. $JANX

Wellington Management Group LLP lessened its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 5.7% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,507,360 shares of the company’s stock after selling 90,290 shares during the period. Wellington Management Group LLP owned 2.47% of Janux Therapeutics worth $23,153,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of Janux Therapeutics during the second quarter valued at about $94,228,000. Janus Henderson Group PLC increased its position in Janux Therapeutics by 13.8% in the 4th quarter. Janus Henderson Group PLC now owns 5,350,453 shares of the company’s stock valued at $73,850,000 after buying an additional 649,341 shares in the last quarter. State Street Corp increased its position in Janux Therapeutics by 103.8% in the 4th quarter. State Street Corp now owns 3,853,951 shares of the company’s stock valued at $53,185,000 after buying an additional 1,962,486 shares in the last quarter. Vanguard Group Inc. raised its stake in Janux Therapeutics by 10.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,417,104 shares of the company’s stock worth $59,074,000 after buying an additional 227,676 shares during the period. Finally, Prosight Management LP raised its stake in Janux Therapeutics by 176.5% during the 4th quarter. Prosight Management LP now owns 2,392,523 shares of the company’s stock worth $33,017,000 after buying an additional 1,527,173 shares during the period. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Janux Therapeutics Trading Up 2.2%

Shares of NASDAQ:JANX opened at $20.24 on Friday. The stock’s 50-day moving average price is $16.59 and its 200-day moving average price is $15.03. Janux Therapeutics, Inc. has a 12-month low of $12.12 and a 12-month high of $35.34. The stock has a market capitalization of $1.24 billion, a P/E ratio of -12.34 and a beta of 2.53.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, August 6th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10). The firm had revenue of $10.27 million during the quarter, compared to the consensus estimate of $19.07 million. As a group, research analysts predict that Janux Therapeutics, Inc. will post -1.76 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Guggenheim reduced their target price on shares of Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Truist Financial reiterated a “buy” rating and issued a $26.00 price objective (down from $80.00) on shares of Janux Therapeutics in a research note on Thursday, June 25th. TD Cowen raised Janux Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Wolfe Research raised Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 target price for the company in a research report on Monday, August 24th. Finally, Stifel Nicolaus set a $35.00 price objective on Janux Therapeutics in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.46.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.